Tag:
Celera
Latest Headlines
Latest Headlines
Quest Diagnostics snags Celera in $344M buyout
Quest Diagnostics is snapping up Celera--along with its expertise in genetics and biomarkers--for $344 million in cash. "Our discovery and validation of new biomarkers has exceeded our capacity to
Celera cuts 50 jobs on Q3 losses
Alameda, CA-based genetic testing company Celera reported net revenues of $31.5 million for the third quarter compared to $40 million for the prior year quarter. The company also saw a net loss of
Smaller layoffs add up to 1,000-plus
A few layoffs here, a few there, a few empty posts unfilled ... and pretty soon, you have 1,000 job cuts. That's the story this week as Amgen, Celera and IMS Health all reduced staffing. On the plus
Celera closing up shop in Rockville
In what the Washington Business Journal describes as the "end of an era," Celera is shuttering its remaining 41,000-square-foot facility in Rockville, MD and laying off 20 of its 25 local staffers.
Translational tool helps ID genetic markers
Disease diagnostics developer Celera is using the InforSense translational research solution to identify genetic markers indicating increased risk of coronary heart disease. The solution allows
Celera completes its corporate transformation
Celera has ended its run as a biotech drug developer, completing its switch to molecular diagnostic testing company and moving its HQ from Rockville, MD to Alameda California. The Baltimore Business
ALSO NOTED: Crucell shares up on TB data; Celera, Merck ink cancer deal; and much more...
> A federal patent office may appeal a court ruling that threw out a new cap limiting the number of times a company can resubmit patent applications. That change was aggressively contested by the
ALSO NOTED: Novartis teams up with MIT; EMEA approves Galvus; and much more...
> Novartis is teaming up with MIT to develop new ways to manufacture drugs. The company will give the university $65 million over 10 years to create a new research program. Report > Galvus, a
Celera acquires Atria assets for $33M
Celera will acquire all of the assets of Atria for approximately $33 million in cash. Atria has a line of human leukocyte antigen (HLA) testing products that are used for identifying potential
ALSO NOTED: Teva invests in stem cell start-up; Anacor files for IPO; Merrion sets terms; and much more...
> Teva is investing $1 million in the stem cell start-up Cell Cure Neurosciences. Report > Anacor
